Viewing Study NCT01067469

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:00 PM
Ignite Modification Date: 2026-01-01 @ 8:34 AM
Study NCT ID: NCT01067469
Status: COMPLETED
Last Update Posted: 2020-03-17
First Post: 2010-02-10
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
Sponsor: M.D. Anderson Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Brain Cancer View
None Glioblastoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None CNS View
None Central Nervous System View
None malignant brain tumor View
None Recurrent Glioblastoma Multiforme View
None GBM View
None Bevacizumab View
None Lomustine View
None CCNU View